On August 25, 2022 Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, reported that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin (Press release, Oncoinvent, AUG 25, 2022, https://www.oncoinvent.com/press-release/oncoinvent-initiates-radspherin-phase-2a-trial/?utm_source=mailpoet&utm_medium=email&utm_campaign=oncoinvent-initiates-radspherin-phase-2a-trial [SID1234618669]). The study is conducted at two sites, the Radium Hospital in Oslo Norway and at the Uppsala University Hospital in Uppsala Sweden and will include a total of thirty patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The start of the RAD-18-002 phase 2A study marks an entry into the next stage of development for both our product candidate Radspherin as well as for Oncoinvent" said Jan A. Alfheim, Chief Executive Officer of Oncoinvent. "This new study takes us a step closer to achieving our primary goal of developing an effective therapy for cancer patients suffering from peritoneal carcinomatosis."
About the RAD-18-002 Study
The phase 2A open-label expansion cohort of the RAD-18-002 clinical trial is designed to assess the safety, tolerability, and anti-tumor activity of Radspherin, an α-emitting radionuclide therapy, administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC. Key objectives in the study include survival benefit as well as acute and long-term safety of the drug product candidate.